Akathisia: An updated review focusing on second-generation antipsychotics

Journal of Clinical Psychiatry

Volumn 70, Issue 5, 2009, Pages 627-643

  Kane, John M ^a   Fleischhacker, Wolfgang W ^b   Hansen, Lars ^c   Perlis, Roy ^d   Pikalov III, Andrei ^e   Assunção Talbott, Sheila ^f  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^f BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHLORPROMAZINE; CLONIDINE; CLOZAPINE; DIPHENHYDRAMINE; HALOPERIDOL; MIRTAZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AKATHISIA; ANTICHOLINERGIC EFFECT; BIPOLAR DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DRUG MEGADOSE; DRUG WITHDRAWAL; HUMAN; MORBIDITY; MOTOR DYSFUNCTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REVIEW; SCHIZOPHRENIA;

AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; HUMANS;

EID: 67049162787     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.08r04210     Document Type: Review

References (164)

1. Dressler D, Benecke R. Diagnosis and management of acute movement disorders. J Neurol 2005;252:1299-1306 (Pubitemid 41699017)
2. Blaisdell GD. Akathisia: a comprehensive review and treatment summary. Pharmacopsychiatry 1994;27:139-146 (Pubitemid 24214276)
3. Braude WM, Barnes TR, Gore SM. Clinical characteristics of akathisia: a systematic investigation of acute psychiatric inpatient admissions. Br J Psychiatry 1983;143:139-150
4. Halstead SM, Barnes TRE, Speller JC. Akathisia: prevalence and associated dysphoria in an in-patient population with chronic schizophrenia. Br J Psychiatry 1994;164:177-183 (Pubitemid 24077352)
5. Barnes TRE, Braude WM. Akathisia variants and tardive dyskinesia. Arch Gen Psychiatry 1985;42:874-878 (Pubitemid 16248512)
6. Sachdev P. The development of the concept of akathisia: a historical overview. Schizophr Res 1995;16:33-45
7. Marder SR. Subjective experiences on antipsychotic medications: synthesis and conclusions. Acta Psychiatr Scand Suppl 2005;427:43-46 (Pubitemid 40780199)
8. Crane GE, Naranjo ER. Motor disorders induced by neuroleptics: a proposed new classification. Arch Gen Psychiatry 1971;24:179-184
9. Fleischhacker WW, Miller CH, Barnas C, et al. The effect of activation procedures on neuroleptic-induced akathisia. Br J Psychiatry 1993;163:781-784 (Pubitemid 23352972)
10. Gruber O, Northoff G, Pflug B. Effect of activation tasks on acute neuroleptic-induced akathisia. Nervenarzt 2000;71:30-37 (Pubitemid 30163176)
11. Gibb WR, Lees AJ. The clinical phenomenon of akathisia. J Neurol Neurosurg Psychiatry 1986;49:861-866 (Pubitemid 16048412)
12. Chung WS, Chiu HP. Drug induced akathisia revisited. Br J Clin Pract 1996;50(5):270-278
13. Miller CH, Mohr F, Umbricht D, et al. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry 1998;59(2):69-75 (Pubitemid 28141238)
14. Barnes TRE. The Barnes Akathisia Rating Scale-revisited. J Psychopharmacol 2003;17:365-370
15. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
16. Chouinard G, Ross-Chouinard A, Annable L, et al. Extrapyramidal rating scale. Can J Neurol Sci I 1980;233
17. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676 (Pubitemid 19154942)
18. Sachdev PS. A rating scale for acute drug-induced akathisia: development, reliability and validity. Biol Psychiatry 1994;35:263-271 (Pubitemid 24118458)
19. Loonen AJ, Doorschot CH, Van Hemert DA, et al. The schedule for the assessment of drug-induced movement disorders (SADIMoD): test-retest reliability and concurrent validity. Int J Neuropsychopharmacol 2000;3:285-296 (Pubitemid 32056621)
20. Inada T, Beasley CM, Tanaka Y, Walker DJ. Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol. Int Clin Psychopharmacol 2003;18:39-48 (Pubitemid 36127060)
21. Kane JM. Extrapyramidal side effects are unacceptable. Eur Neuropsychopharmacol 2001;11(suppl 4):S397-S403 (Pubitemid 32928375)
22. Miller CH, Fleischhacker WW. Managing antipsychotic-induced acute and chronic akathisia. Drug Saf 2000;22(1):73-81 (Pubitemid 30058028)
23. Nelson DE. Akathisia-a brief review. Scot Med J 2001;46:133-134
24. Sachdev P. The identification and management of drug induced akathisia. CNS Drugs 1989;4:28-46
25. Sachdev P. Akathisia and Restless Legs. Cambridge, UK: Cambridge University Press; 1995:49-50, 162
26. Hirose S. The causes of underdiagnosing akathisia. Schizophr Bull 2003;29:547-558 (Pubitemid 37339389)
27. Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ 2005;172(13):1703-1711 (Pubitemid 40896865)
28. Gogtay N, Sporn A, Alfaro CL, et al. Clozapine-induced akathisia in children with schizophrenia. J Child Adolesc Psychopharmacol 2002;12:347-349 (Pubitemid 36169287)
29. Marsden CD, Jenner P. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med 1980;10:55-72 (Pubitemid 11141134)
30. Lipinski JF, Zubenko GS, Barreira P, et al. Propranolol in the treatment of neuroleptic-induced akathisia. Lancet 1983;2:685-686
31. Miller CH, Fleischhacker WW, Ehrmann H, et al. Treatment of neurolepticinduced akathisia with the 5-HT2 antagonist ritanserin. Psychopharmacol Bull 1990;26:373-376 (Pubitemid 20386912)
32. Stryjer R, Strous RD, Bar F, et al. Treatment of neuroleptic-induced akathisia with the 5-HT2A antagonist trazodone. Clin Neuropharmacol 2003;26:137-141 (Pubitemid 36676291)
33. Strous RD, Stryjer R, Maayan R, et al. Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial. Psychoneuroendocrinology 2007;32:96-105 (Pubitemid 46274013)
34. Caroff SN, Mann SC, Campbell EC, et al. Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry 2002;63(suppl 4):12-19 (Pubitemid 34242106)
35. Kyriakos D, Bozikas VP, Garyfallos, et al. Tardive nocturnal akathisia due to clozapine treatment. Int J Psychiatry Med 2005;35:207-211 (Pubitemid 41638951)
36. Friedman JH. Atypical antipsychotics have very different adverse effect profiles and should not be lumped together. Arch Intern Med 2006;166:586-593
37. Hirose T, Uwahodo Y, Yamada S, et al. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J Psychopharmacol 2004;18:375-383 (Pubitemid 39382565)
38. Lieberman JA. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs 2004;18:251-267 (Pubitemid 38393435)
39. Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry 1999;60(suppl 10):5-14 (Pubitemid 29237170)
40. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000;68:29-39
41. McIntyre RS, Konarski JZ. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry 2005;66(suppl 3):28-36 (Pubitemid 40461409)
42. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60(7):681-690 (Pubitemid 36818630)
43. Potkin SG, Gharabawi GM, Greenspan AJ, et al. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr Res 2006;85:254-265 (Pubitemid 43947539)
44. Beasley CM Jr, Sanger T, Satterlee W, et al. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl) 1996;124:159-167 (Pubitemid 126424654)
45. Beasley CM Jr, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14(2):111-123 (Pubitemid 26050500)
46. Carlson CD, Cavazzoni PA, Berg PH, et al. An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. J Clin Psychiatry 2003;64(8):898-906 (Pubitemid 37022755)
47. Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 1997;54(6):549-557 (Pubitemid 27258553)
48. Buckley PF. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials. Curr Med Res Opin 2004;20:1357-1363 (Pubitemid 39361338)
49. Keck P Jr, Buffenstein A, Ferguson J, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berl) 1998;140:173-184 (Pubitemid 28538477)
50. Daniel DG, Zimbroff DL, Potkin SG, et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 1999;20(5):491-505 (Pubitemid 29123876)
51. Keck PE Jr, Reeves KR, Harrigan EP. Ziprasidone Study Group. Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies. J Clin Psychopharmacol 2001;21(1):27-35 (Pubitemid 32096747)
52. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63(9):763-771
53. Pigott TA, Carson WH, Saha AR, et al. Aripiprazole Study Group. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003;64(9):1048-1056 (Pubitemid 37158250)
54. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61:123-136 (Pubitemid 36513927)
55. Cutler AJ, Marcus RN, Hardy SA, et al. The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia. CNS Spectr 2006;11:691-702 (Pubitemid 44449654)
56. Andrezina R, Josiassen RC, Marcus RN, et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology 2006;188:281-292 (Pubitemid 44387456)
57. Tran-Johnson TK, Sack DA, Marcus RN, et al. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2007;68(1):111-119 (Pubitemid 46220132)
58. Davidson M, Emsley R, Kramer M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 2007;93:117-130 (Pubitemid 46817944)
59. Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 2007;90:147-161 (Pubitemid 46178537)
60. Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry 1999;156(5):702-709
61. Yatham LN, Paulsson B, Mullen J, et al. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J Clin Psychopharmacol 2004;24:599-606 (Pubitemid 39518654)
62. Keck PE Jr, Versiani M, Potkin S, et al. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003;160:741-748 (Pubitemid 41079608)
63. Potkin SG, Keck PE Jr, Segal S, et al. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol 2005;25:301-310 (Pubitemid 41065070)
64. Keck PE Jr, Calabrese JR, McQuade RD, et al, for the Aripiprazole Study Group. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006;67(4):626-637 (Pubitemid 43764240)
65. Sachs G, Sanchez R, Marcus R, et al, on behalf of the Aripiprazole Study Group. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol 2006;20(4):536-546 (Pubitemid 43875183)
66. Keck PE Jr, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003;160:1651-1658 (Pubitemid 41079552)
67. Claghorn J, Honigfeld G, Abuzzahab FS Sr, et al. The risks and benefits of clozapine vs chlorpromazine. J Clin Psychopharmacol 1987;7(6):377-384 (Pubitemid 18006084)
68. Cohen BM, Keck PE, Satlin A, et al. Prevalence and severity of akathisia in patients on clozapine. Biol Psychiatry 1991;29:1215-1219
69. Peacock L, Solgaard T, Lublin H, et al. Clozapine versus typical antipsychotics: a retro- and prospective study of extrapyramidal side effects. Psychopharmacology (Berl) 1996;124:188-196 (Pubitemid 126424655)
70. Kurz M, Hummer M, Oberbauer H, et al. Extrapyramidal side effects of clozapine and haloperidol. Psychopharmacology (Berl) 1995;118:52-56
71. Ceskova E, Svestka J. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry 1993;26:121-124 (Pubitemid 23263240)
72. Rosebush PI, Mazurek MF. Neurologic side effects in neuroleptic- naïve patients treated with haloperidol or risperidone. Neurology 1999;52:782-785 (Pubitemid 29120185)
73. Bouchard RH, Merette C, Pourcher E, et al. Longitudinal comparative study of risperidone and conventional neuroleptics for treating patients with schizophrenia. The Quebec Schizophrenia Study Group. J Clin Psychopharmacol 2000;20(3):295-304 (Pubitemid 30318357)
74. Marder SR, Glynn SM, Wirshing WC, et al. Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. Am J Psychiatry 2003;160:1405-1412 (Pubitemid 41070914)
75. Wirshing DA, Marshall BD Jr, Green MF, et al. Risperidone in treatmentrefractory schizophrenia. Am J Psychiatry 1999;156:1374-1379
76. Tollefson GD, Beasley CM Jr, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-465 (Pubitemid 27147597)
77. Leelahanaj T, Kongsakon R, Netrakom P. A 4-week, double-blind comparison of olanzapine with haloperidol in the treatment of amphetamine psychosis. J Med Assoc Thai 2005;88(suppl 3):S43-S52
78. Dossenbach MR, Folnegovic-Smalc V, Hotujac L, et al, Olanzapine HGCH Study Group. Double-blind, randomized comparison of olanzapine versus fluphenazine in the long-term treatment of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004;28(2):311-318
79. Rosenheck R, Perlick D, Bingham S, et al; Department of Veterans Affairs Cooperative Study Group on the Cost-Effectiveness of Olanzapine. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003;290:2693-2702
80. Kennedy JS, Jeste D, Kaiser CJ, et al. Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial. Int J Geriatr Psychiatry 2003;18:1013-1020 (Pubitemid 37479374)
81. Lieberman JA, Tollefson G, Tohen M, et al, HGDH Study Group. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003;160(8):1396-1404 (Pubitemid 41070913)
82. Breier A, Hamilton SH. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biol Psychiatry 1999;45:403-411 (Pubitemid 29130436)
83. Conley RR, Tamminga CA, Bartko JJ, et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry 1998;155:914-920 (Pubitemid 28307603)
84. Sanger TM, Leiberman JA, Tohen M, et al. Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry 1999;156:79-87 (Pubitemid 29034883)
85. Beasley CM Jr, Hamilton SH, Crawford AM, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997;7:125-137 (Pubitemid 27240346)
86. Nemeroff CB. Dosing the antipsychotic medication olanzapine. J Clin Psychiatry 1997;58(suppl 10):45-49 (Pubitemid 27333180)
87. Wright P, Lindborg SR, Birkett M, et al. Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment. Can J Psychiatry 2003;48:716-721 (Pubitemid 38197030)
88. Breier A, Meehan K, Birkett M, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002;59:441-448 (Pubitemid 34477680)
89. McIntyre RS, Brecher M, Paulsson B, et al. Quetiapine or haloperidol as monotherapy for bipolar mania: a 12-week, double-blind, randomized, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol 2005;15:573-585 (Pubitemid 41219629)
90. Glick ID, Marder SR. Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2005;66(5):638-641 (Pubitemid 40733708)
91. Aravanitis LA, Miller, BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997;42(4):233-246
92. Hirsch SR, Kissling W, Bauml J, et al. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J Clin Psychiatry 2002;63(6):516-523 (Pubitemid 34680361)
93. Brook S, Walden J, Benattia I, et al. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. Psychopharmacology (Berl) 2005;178:514-523 (Pubitemid 40486992)
94. Kasper S, Leman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003;6(4):325-337 (Pubitemid 38146250)
95. Vieta E, Bourin M, Sanchez R, et al. Effectiveness of aripiprazole v haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry 2005 Sep;187:235-242 (Pubitemid 41306104)
96. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63:1079-1087 (Pubitemid 44498387)
97. Meltzer HY, Alphs L, Green AI, et al, International Suicide Prevention Trial study group. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003;60(1):82-91
98. Bitter I, Dossenbach MR, Brook S, et al, Olanzapine HGCK Study Group. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004;28(1):173-180
99. Kelly DL, Conley RR, Richardson CM, et al. Adverse effects and laboratory parameters of high-dose olanzapine vs clozapine in treatment-resistant schizophrenia. Ann Clin Psychiatry 2003;15(3-4):181-186 (Pubitemid 38176337)
100. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorder. J Clin Psychopharmacol 1997;17:407-418 (Pubitemid 27414397)
101. Ho BC, Miller D, Nopoulos P, et al. A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. J Clin Psychiatry 1999;60(10):658-663 (Pubitemid 29503645)
102. Alvarez E, Ciudad A, Olivares JM, et al. A randomized, 1-year followup study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia. J Clin Psychopharmacol 2006;26:238-249 (Pubitemid 43804615)
103. Gureje O, Miles W, Keks N, et al. Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand. Schizophr Res 2003;61:303-314 (Pubitemid 36519178)
104. Van Bruggen J, Tijssen J, Dingemans P, et al. Symptom response and side-effects of olanzapine and risperidone in young adults with recent onset schizophrenia. Int Clin Psychopharmacol 2003;18:341-346 (Pubitemid 38183487)
105. Mozes T, Ebert T, Michal SE, et al. An open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia. J Child Adolesc Psychopharmacol 2006;16:393-403 (Pubitemid 44681460)
106. Mintzer JE, Mullen JA, Sweitzer DE. A comparison of extrapyramidal symptoms in older outpatients treated with quetiapine or risperidone. Curr Med Res Opin 2004;20:1483-1491
107. Addington DE, Pantelis C, Dineen M, et al. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. J Clin Psychiatry 2004;65(12):1624-1633
108. Simpson GM, Glick ID, Weiden PJ, et al. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry 2004;161:1837-1847 (Pubitemid 39314678)
109. Breier A, Berg PH, Thakore JH, et al. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry 2005;162:1879-1887 (Pubitemid 41428617)
110. McQuade RD, Stock E, Marcus R, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 2004;65(suppl 18):47-56
111. Chrzanowski WK, Marcus RN, Torbeyns A, et al. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl) 2006;189:259-266 (Pubitemid 44691547)
112. Zimbroff D, Warrington L, Loebel A, et al. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study. Int Clin Psychopharmacol 2007;22:363-370 (Pubitemid 47530841)
113. Lieberman JA, Stroup TS, McEvoy JP, et al, for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223
114. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163:600-610 (Pubitemid 44464569)
115. Stroup TS, Lieberman JA, McEvoy JP. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006;163:611-622 (Pubitemid 44464570)
116. McEvoy JP, Lieberman JA, Perkins DO, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007;164:1050-1060 (Pubitemid 47121394)
117. Ghaemi SN, Hsu DJ, Rosenquist KJ, et al. Extrapyramidal side effects with atypical neuroleptics in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2006;30(2):209-213 (Pubitemid 43288060)
118. Brune M. The incidence of akathisia in bipolar disorder treated with neuroleptics-a preliminary report. J Affect Disord 1999;53:175-177 (Pubitemid 29232357)
119. Kane JM, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796 (Pubitemid 18222922)
120. Kane JM, Meltzer HY, Carson WH Jr, et al, Aripiprazole Study Group. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry 2007;68(2):213-223 (Pubitemid 46362642)
121. Cem Atbaşoglu E, Schultz SK, Andreasen NC. The relationship of akathisia with suicidality and depersonalization among patients with schizophrenia. J Neuropsychiatry Clin Neurosci 2001;13(3):336-341 (Pubitemid 32743711)
122. Drake RE, Ehrlich J. Suicide attempts associated with akathisia. Am J Psychiatry 1985;142:499-501 (Pubitemid 15108220)
123. Bourgeois M, Swendsen T, Young E, et al. Awareness of disorder and suicide risk in the treatment of schizophrenia: results of the international suicide prevention trial. Am J Psychiatry 2004;161:1494-1496 (Pubitemid 38989107)
124. Oquendo MA, Galfalvy H, Russo S, et al. Prospective study of clinical predictors of suicidal acts after a major depressive episode in patients with major depressive disorder or bipolar disorder. Am J Psychiatry 2004;161:1433-1441 (Pubitemid 38989097)
125. Hansen L. A critical review of akathisia, and its possible association with suicidal behaviour. Hum Psychopharmacol 2001;16:495-505 (Pubitemid 33014646)
126. Hansen L, Jones R, Kingdon D. No association between akathisia or parkinsonism and suicidality in treatment resistant schizophrenia. J Psychopharmacol 2004;18:384-387 (Pubitemid 39382566)
127. Taylor D, Paton C, Kerwin R. The Maudsley 2003 Prescribing Guidelines. 7th ed. London, UK: Marin Dunitz; 2002
128. Fleischhacker WW, Roth SD, Kane JM. The pharmacologic treatment of neuroleptic-induced akathisia. J Clin Psychopharmacol 1990;10:12-21 (Pubitemid 20096217)
129. Pierre JM. Extrapyramidal symptoms with atypical antipsychotic: incidence, prevention, and management. Drug Saf 2005;28:191-208 (Pubitemid 40364887)
130. Guidance on the use of the newer (atypical) antipsychotic drugs for the treatment of schizophrenia. London, UK: National Institute of Clinical Excellence (NICE), National Health Service. Technology Appraisal Guidance No. 43. June 2002. Available at: http://www.nice.org.uk/nicemedia/pdf/43- Antipsychotics-summary.pdf. Accessed Sept 16, 2008
131. Suppes T, Dennehy EB, Hirschfeld RM, et al, Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry 2005;66(7):870-886
132. Perlis RH, Keck PE. The Texas implementation of medication algorithms update for treatment of bipolar I disorder. J Clin Psychiatry 2005;66(7):818-820 (Pubitemid 41032821)
133. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Bipolar Disorder (revision). Am J Psychiatry 2002;159(suppl 4):1-50 (Pubitemid 34274969)
134. Adler LA, Angrist B, Peselow E, et al. Clonidine in neuroleptic-induced akathisia. Am J Psychiatry 1987;144:235-236 (Pubitemid 17011405)
135. Nishikawa T, Koga I, Uchida Y, et al. Treatment of tardive akathisia with clonidine. Kurume Med J 1990;37:185-187
136. Vinson DR. Diphenhydramine in the treatment of akathisia induced by prochlorperazine. J Emerg Med 2004;26(3):265-270 (Pubitemid 38340823)
137. Koertner A. Evidence-based emergency medicine/systematic review abstract: should anticholinergic drugs be used for neuroleptic-induced acute akathisia? Ann Emerg Med 2007;50(3):346-348
138. Parlak I, Erdur B, Parlak M, et al. Midazolam vs diphenhydramine for the treatment of metoclopramide-induced akathisia: a randomized controlled trial. Acad Emerg Med 2007;14(8):715-721 (Pubitemid 47064420)
139. Fischel T, Hermesh H, Aizenberg D, et al. Cyproheptadine versus propranolol for the treatment of acute neuroleptic-induced akathisia: a comparative double-blind study. J Clin Psychopharmacol 2001;21(6):612-615 (Pubitemid 33116663)
140. Van Putten T. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 1974;31:67-72
141. Van Putten T, Marder SR. Behavioral toxicity of antipsychotic drugs. J Clin Psychiatry 1987;48(suppl):13-19 (Pubitemid 17158091)
142. Van Putten T, Marder SR, Mintz J. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry 1990;47(8):754-758 (Pubitemid 20229966)
143. Weiden PJ, Mann JJ, Dixon L, et al. Is neuroleptic dysphoria a healthy response? Comp Psychiatry 1989;30(6):546-552
144. Berardi D, Giannelli A, Barnes TR. Clinical correlates of akathisia in acute psychiatric inpatients. Int Clin Psychopharmacol 2000;15:215-219 (Pubitemid 30433522)
145. Jones M, Bennett J, Gray R, et al. Pharmacological management of akathisia in combination with psychological interventions by a mental health nurse consultant. J Psychiatr Ment Health Nurs 2006;13:26-32
146. Hansen LK. Akathisia-seen from the patients' perspective. J Psychopharmacol 2008 Jan 30 [Epub ahead of print]
147. Hirschfeld RMA, Guideline Watch: Practice Guideline for the Treatment of Patients With Bipolar Disorder. Arlington, Va: American Psychiatric Association; 2005. Available at: http://www.psych.org/psych-pract/treatg/pg/prac-guide.cfm. Accessibility confirmed Sept 16, 2008
148. Oral ET, Altinbas K, Demirkiran S. Sudden akathisia after a ziprasidone dose reduction. Am J Psychiatry 2006;163(3):546 (Pubitemid 44469404)
149. Rosebush PI, Kennedy K, Dalton B, et al. Protracted akathisia after risperidone withdrawal. Am J Psychiatry 1997;154:437-438 (Pubitemid 27098304)
150. Gardner DM, Baldessarini RJ, Benzo J, et al. Switching between clozapine and risperidone treatment. Can J Psychiatry 1997;42:430-431 (Pubitemid 27288395)
151. Sachdev PS, Saharov T. The effects of b-adrenoceptor antagonists on a rat model of neuroleptic-induced akathisia. Psychiatry Res 1997;72:133-140 (Pubitemid 27425455)
152. Bartels M, Heide K, Mann K. Treatment of akathisia with lorazepam: an open trial. Pharmacopsychiatry 1987;20:51-53 (Pubitemid 17049359)
153. Kutcher S, MacKenzie S, Galaarraga J, et al. Clonazepam treatment of adolescents with neuroleptic induced akathisia. Am J Psychiatry 1987;144:823-824
154. Kutcher S, Williamson P, MacKenzie S, et al. Successful clonazepam treatment of neuroleptic induced akathisia in older adolescents and young adults: a double blind study. J Clin Psychopharmacol 1989;9:403-406 (Pubitemid 20023020)
155. Donlon PT. The therapeutic use of diazepam for akathisia. Psychosomatics 1973;14:222-225
156. Rathbone J, Soares-Weiser K. Anticholinergics for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev 2006;4:CD003727
157. Fischel T, Hermesh H, Aizenberg D, et al. Cyproheptadine versus propanolol for the treatment of acute neuroleptic-induced akathisia: a comparative double-blind study. J Clin Psychopharmacol 2001;21:612-615 (Pubitemid 33116663)
158. Weiss D, Aizenberg D, Hermesch H, et al. Cyproheptadine treatment in neuroleptic-induced akathisia. Br J Psychiatry 1995;167:483-486 (Pubitemid 26194150)
159. Zubenko GS, Cohen BM, Lipinski JF Jr, et al. Use of clonidine in treating neuroleptic-induced akathisia. Psychiatry Res 1984;13:253-259 (Pubitemid 15219741)
160. Adler LA, Reiter S, Corwin J, et al. Differential effects of propanolol and benztropine in patients with neuroleptic induced akathisia. Psychopharmacol Bull 1987;23:519-521 (Pubitemid 18008466)
161. Poyurovsky M, Pshianian A, Weizman R, et al. Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia: a randomized, double-blind, placebo- and propanolol-controlled trial. Biol Psychiatry 2006;59:1071-1077 (Pubitemid 43849656)
162. Ranjan S, Chandra PS, Chaturvedi SK, et al. Atypical antipsychoticinduced akathisia with depression: therapeutic role of mirtazapine. Ann Pharmacother 2006;40:771-774
163. Vinson DR, Drotts DL. Diphenhydramine for the prevention of akathisia induced by prochlorperazine: a randomized, controlled trial. Ann Emerg Med 2001;37(2):125-131 (Pubitemid 32142957)
164. Konig P, Chwatal K, Havelec L, et al. Amantadine versus biperiden: a double-blind study of treatment efficacy in neuroleptic extrapyramidal movement disorders. Neuropsychobiology 1996;33(2):80-84 (Pubitemid 26089380)